Mapatumumab

BIOLOGICAL5 trials

Sponsors

Human Genome Sciences Inc., Human Genome Sciences Inc., a GSK Company, University Medical Center Groningen

Conditions

Advanced Cervical CancerCarcinoma, HepatocellularHepatocellular CarcinomaMultiple MyelomaNon Small Cell Lung Cancer

Phase 1

A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

CompletedNCT00712855

Human Genome Sciences Inc., a GSK CompanyHepatocellular Carcinoma

Start: 2008-06-30End: 2012-08-31Updated: 2012-10-30

Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer

CompletedNCT01088347

University Medical Center GroningenAdvanced Cervical Cancer

Start: 2010-03-31End: 2014-03-31Updated: 2024-04-19

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

CompletedNCT01258608

Human Genome Sciences Inc., a GSK CompanyCarcinoma, Hepatocellular

Start: 2011-02-08End: 2017-11-29Updated: 2018-12-19

Phase 2

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

CompletedNCT00315757

Human Genome Sciences Inc.Multiple Myeloma

Start: 2006-05-31End: 2010-10-31Updated: 2013-08-08

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

CompletedNCT00583830

Human Genome Sciences Inc.Non Small Cell Lung Cancer

Start: 2007-01-31End: 2011-02-28Updated: 2013-08-08

Related Papers

Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2014-05-201 citations